Paclitaxel Or Oxaliplatin-based Chemotherapy In The Treatment Of Advanced Gastric Cancer

Objective To evaluate the efficacy and toxicity of Paclitaxel-based or Oxaliplatin-based chemotherapy in the treatment of advanced gastric cancer.Methods Totally thirty patients with advanced gastric cancer (metas -tatic or recurrent gastric cancer) treated with Paclitaxel-based regimens or Oxaliplatin-based regimen: Paclitaxel plus 5-fluorouracil and Leucovorin 14 patients, Paclitaxel plus cisplatin patients, Oxaliplatin plus 5-fluorouracil and Leucovorin 8 patients. Results Thirty patients were evaluated for clinical response. There were 4 complete responses (13.33%), PR 7 (23.33%), SD 11 (36.67%), PD 8 (26.67%), the total response rate (RR) was 36.67%. The median survival time of 26 patients was 12 months (4-31 months), as 4 patients were lost of follow-up. The one-year survival rate was 50. 00%, the two-year survival rate was 7. 69%. Then among the 22 patients who were treated with Paclitaxel-based regimens, CR 4 (18.18%), PR 4 (18.18%), SD 9 (40.91%), PD 5 (22.73%), the total response rate was 36.36%; The median survival time in this group was 11 months(4-31 months, total 3 patients were lost of follow-up). Among the other 8 patients treated with Oxaliplatin plus 5-fluorouracil and Leucovorin, there was no complete response, PR 3 (37.50%), SD 2 (25.00%), PD 3 (37.50%), RR 37. 50%; The median survival time in this group was 14 months(6-23 months, only 1 patients were lost of follow-up). There was no statistic difference between the response rate(36.36% versus 37.50%, p>0.05). Among the 22 patients treated with Paclitaxel-based chemotherapy, the most common hematological toxicity was neutropenia (91.0%), grade3/4 neutropenia developed in 4 patientd and 18.6%; The most common non-hematological toxicities were muscular soreness and arthralgia (77.2%), alopecia (85.7%), peripheral neuropathy (50.1%). No treatment-related death was observed.Conclusion Both Paclitaxel-based chemotherapy and Oxaliplatin-based chemotherapy are effective and well tolerated regimens in the treatment of advanced gastric cancer, which can be practiced safely.